Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mandeep Kaur

Psychiatry Fayetteville, NC Medical Doctor

NPI 1215298856 CMS profile 796299

711 Executive Pl Fl 3, Fayetteville, NC 28305

Open in the dashboard

General payments

$2,178

144 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mandeep Kaur of Fayetteville, NC is reported in the CMS Open Payments database as having received $2,178 across 144 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 80th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $56 3
2022 General $81 4
2021 General $1,082 72
2020 General $177 11
2019 General $783 54

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mandeep Kaur
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Mandeep Kaur were reported at $56. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Mandeep Kaur Psychiatry median Middle half National median
2019 $783 $184 $59–$605 $163
2020 $177 $119 $36–$372 $114
2021 $1,082 $143 $43–$576 $132
2022 $81 $153 $50–$590 $149
2023 $0 $170 $56–$651 $160
2024 $0 $179 $57–$673 $164
2025 $56 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Otsuka America Pharmaceutical, Inc. $286 19 payments
  2. Alkermes, Inc. $245 13 payments
  3. Teva Pharmaceuticals USA, Inc. $200 21 payments
  4. AbbVie, Inc. $190 11 payments
  5. Janssen Pharmaceuticals, Inc $178 11 payments
  6. Lundbeck LLC $178 10 payments
  7. Neurocrine Biosciences, Inc. $155 8 payments
  8. Vanda Pharmaceuticals Inc. $126 7 payments
  9. Allergan Inc. $123 15 payments
  10. Indivior Inc. $113 6 payments
  11. Other $384 23 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,178 144 payments
Products named General payments · program years 2019–2025
  1. ARISTADA Cns $226 12 payments
  2. ARISTADA Cns $226 12 payments
  3. ARISTADA Cns $202 11 payments
  4. ARISTADA Cns $202 11 payments
  5. AUSTEDO $200 21 payments
  6. VRAYLAR $190 11 payments
  7. ABILIFY MAINTENA $181 13 payments
  8. ARISTADA INITIO $171 9 payments
  9. INVEGA SUSTENNA $162 10 payments
  10. REXULTI $156 9 payments
  11. Other $1,318 82 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 17 drugs

Part D claims

369

Median for Psychiatry: 574

Drug cost

$3,346

Median for Psychiatry: $27,624

Branded share of claims

14.1%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Aripiprazole Generic 15 $811
Buspirone Hcl Generic 29 $401
Bupropion Xl Bupropion Hcl Brand 27 $329
Trazodone Hcl Generic 65 $277
Duloxetine Hcl Generic 14 $264
Venlafaxine Hcl Er Venlafaxine Hcl Brand 25 $244
Clonazepam Generic 26 $189
Sertraline Hcl Generic 29 $183
Lamotrigine Generic 22 $140
Olanzapine Generic 12 $88

The 10 drugs with the highest cost, of 17 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 6 billing codes

Paid by Medicare

$3,629

Medicare's payments for the services billed

Medicare patients

39

Average age 61

Services billed

63

28 women, 11 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Depression 67%
High blood pressure 62%
Arthritis 49%
Diabetes 38%
COPD 33%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

144 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record